A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Clinical trial NCT05908409 · RECRUITING

Trial details

NCT number: NCT05908409
Sponsor: IDP Discovery Pharma S.L.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma (MM)Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Double Hit Lymphoma High Grade B-Cell Lymphoma, Not Otherwise Specified Chronic Lymphocytic Leukemia (CLL)Triple Hit Lymphoma

Start date: 2023-06-05
Primary completion: 2025-12-22
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.